A Single-Site Study To Evaluate The Irritation Potential Of Topically Applied ATx201 In Healthy Human Volunteers on Intact and Abraded Skin
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Cumulative Irritation Scores
研究概览
简要总结
This is a Phase I single-site study to evaluate the irritation potential of topically applied ATx201 GEL, 2% and 4%, along with positive and negative control and placebo control (ATx201 GEL Placebo), in healthy human subjects on intact and abraded skin. Approximately thirty-six (36) healthy adult subjects will receive all the test articles to provide for 30 subjects to complete the study. The test articles will be applied to the upper back of the subjects during the study, and the placement of the test articles will be randomized. Abraded skin will be induced using sequential tape stripping.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Judged by the Investigator to have no health conditions that would impact the safety of the subject during participation.
- •Body Mass Index (BMI) to be no less than 19.0 and no greater than 36.0 kg/m² (inclusive).
- •Demonstrates a Fitzpatrick skin score of I - IV
- •Female subjects must agree to use a medically acceptable contraceptive method
- •Willing to refrain from excessive consumption of sodium (> 2,400 mg/day or > 1 teaspoon equivalent/day) in food or beverage 48 hours prior to Day 1 through EOS Visit.
- •Willing to shower using the same non-medicated soap/cleansers, and abstain from excessive sun exposure (including tanning salons) from the Screening Visit through EOS Visit.
排除标准
- •any clinical investigational product within 30 days prior to Day 1 through EOS Visit
- •recent or current medical condition that, in the opinion of the Investigator, might significantly affect an immunological response to topical ATx201 or compromise the safety of the subject.
- •history of diabetes mellitus, clinically significant asthma (acceptable if no episode within 5 years prior to Day 1), or currently diagnosed with hypertension or circulatory disease.
- •use of any medication on a regular basis within 14 days prior to Day 1 through EOS that could change peripheral blood flow, with the exception of any prescribed birth control method or hormone replacement therapy.
- •use of any oral, nasal or topical corticosteroids, or oral or topical retinoids (other than Vitamin A at normal dietary amounts) within 14 days prior to the Screening Visit through EOS Visit.
- •intending to start, stop, or change the dose of any prescription or over-the-counter (OTC) medication within 48 hours prior to Day 1 through EOS Visit.
- •use of any prescription or OTC topical medications on the upper back within 30 days prior to Day 1 through EOS Visit.
- •history of sensitivity/allergy to any ingredients found in the ATx201 formulation or has a history of adverse reactions to topical medications.
- •significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
- •history of significant skin conditions or disorders such as psoriasis, atopic dermatitis, etc.
- •history of significant dermatologic cancers, for example, melanoma or squamous cell carcinoma.
- •displays an obvious difference in skin color on the upper back or the presence of a skin anomaly such as a recent sunburn, scratch, scar tissue, tattoo, or coloration that would interfere with placement of test sites, their assessment, and their potential response to the study drug or that could compromise the safety of the subject.
- •smoking or use of tobacco or nicotine delivery products within 14 days prior to Day 1 through EOS Visit.
- •female who is pregnant, lactating, breastfeeding, or intends to become pregnant over the course of the study.
- •history of drug or alcohol addiction or abuse within the past year.
- •caffeine intake greater than 500 mg per day (for example, 1 cup of coffee contains approximately 85 mg of caffeine, tea approximately 25 mg, soft drinks up to 115 mg, energy drinks 90 - 422 mg).
- •unwilling to abstain from energy drinks, alcohol, and excessive caffeine (> 500 mg/day) for 48 hours prior to Day 1 through EOS Visit.
- •reports having donated blood or plasma within 48 hours prior to Day 1 through EOS Visit.
研究组 & 干预措施
ATx201 GEL, 2% - intact skin
ATx201 GEL, 2% applied intact skin
干预措施: ATx201 Gel 2% (Drug)
ATx201 GEL, 4% - intact skin
ATx201 GEL, 4% applied to intact skin
干预措施: ATx201 Gel 4% (Drug)
ATx201 GEL, 2% - abraded skin
ATx201 GEL, 2% applied to abraded skin
干预措施: ATx201 Gel 2% (Drug)
ATx201 GEL, 4% - abraded skin
ATx201 GEL, 4% applied to abraded skin
干预措施: ATx201 Gel 4% (Drug)
ATx201 GEL Placebo - intact skin
ATx201 GEL Placebo applied to intact skin
干预措施: ATx201 Placebo (Drug)
ATx201 GEL Placebo - abraded skin
ATx201 GEL Placebo applied to abraded skin
干预措施: ATx201 Placebo (Drug)
Negative Irritant Control - intact skin
Negative (low) Irritant Control applied to intact skin
干预措施: Negative Control (Drug)
Negative Irritant Control - abraded skin
Negative (low) Irritant Control applied to abraded skin
干预措施: Negative Control (Drug)
Positive Irritant Control - intact skin
Positive (high) Irritant Control applied to intact skin
干预措施: Positive Control (Drug)
结局指标
主要结局
Cumulative Irritation Scores
时间窗: 21 days
the sum of the combined Dermal response and Other Effects Score
次要结局
- Incidence of Test Article Discontunation(21 days)
- Time of combined Dermal response and Other Effects Score >=3(21 days)
- Time to test article discontinuation(21 days)